2011•Advances in Cardiovascular DiseasesRequires access

Review of Nebivolol in Patient with Chronic Heart Failure

Liao Zhong-you

Abstract

Nebivolol is a third-generation β-blocker with high β1/β2 selectivity.Nebivolol not only inhibits the sympathetic nervous system,improves heart failure prognosis,but also has vasodilating properties through the stimulation of the production of nitric oxide.Nebivolol is the only β-blocker shown to be effective in elderly heart failure patients,regardless of their left ventricular ejection fraction.Future studies will be needed to further clarify nebivolol's role in the treatment of patients with heart failure.

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Nebivolol, Medicine, Heart failure, Cardiology, Vasodilation, Nitric oxide, Ejection fraction, Internal medicine